Table 1.
Baseline characteristics by treatment group
| Variables | Ceftaroline (n = 67) |
Daptomycin (n = 342) |
P-value |
|---|---|---|---|
| Age (years), median (IQR) | 63 (59–71) | 60 (55–68) | 0.0158 |
| Male, % | 96% | 95% | 1.000 |
| Married, % | 49% | 46% | 0.6177 |
| Race & Ethnicity, % | |||
| White, non-Hispanic | 68% | 59% | 0.1595 |
| Black, non-Hispanic | 19% | 30% | 0.0265 |
| Hispanic | 9% | 7% | 0.6864 |
| Other, non-Hispanic | 4% | 2% | 0.2242 |
| Missing | 0% | 2% | 0.3634 |
| Charlson comorbidity score, median (IQR) | 6 (4–9) | 5 (3–7) | 0.0093 |
| Comorbidities, % | |||
| Congestive heart failure | 33% | 23% | 0.0994 |
| COPD | 36% | 25% | 0.0784 |
| Cerebrovascular disease | 21% | 15% | 0.2603 |
| Dementia | 1% | 2% | 1.000 |
| Diabetes (complications) | 30% | 19% | 0.0468 |
| Diabetes (no complications) | 58% | 46% | 0.0789 |
| Hemi/paraplegia | 1% | 6% | 0.1482 |
| HIV | 0% | 1% | 1.000 |
| AIDS | 1% | 1% | 0.5932 |
| Liver (mild) | 3% | 6% | 0.5498 |
| Liver (mod/severe; cirrhosis) | 7% | 8% | 1.000 |
| Cancer | 24% | 16% | 0.1533 |
| Leukemia | 6% | 3% | 0.2838 |
| Metastatic cancer | 4% | 3% | 0.7104 |
| Myocardial infarction | 9% | 10% | 0.7467 |
| Peptic ulcer disease | 3% | 4% | 1.000 |
| Peripheral vascular disease | 25% | 20% | 0.3487 |
| Renal disease | 34% | 34% | 0.9852 |
| Rheumatic disease | 4% | 2% | 0.1696 |
| Dyslipidemia | 55% | 46% | 0.1499 |
| Hypertension | 82% | 73% | 0.1077 |
| Hemodialysis | 3% | 4% | 1.000 |
| Prior hospitalization (past 90 days), % | 31% | 31% | 0.955 |
| Prior antibiotics (past 90 days), % | 66% | 61% | 0.4524 |
| Intensive Care Unit (ICU), % | 22% | 29% | 0.2857 |
| Weight (lbs), median (IQR) | 202 (164–251) | 200 (169–240) | 0.832 |